Stocks crept lower on Friday as a selloff in health care extended into its second day, this time led by Amgen (AMGN) shares. Biogen (BIIB) tanked the sector a day earlier following an analyst downgrade. Amgen fell after its cholesterol drug showed weaker results than anticipated. Repatha reduced the risk of heart attacks and strokes by 15%, less than a target of at least 20%. Consumer sentiment ticked up at a faster pace in March than expected, according to a preliminary reading of the University of Michigan index. Barclays analysts note that strength supports GDP growth in the near term. Tiffany & Co. (TIF) rose after topping fourth-quarter estimates and providing upbeat guidance. Same-store sales over its holiday quarter came in flat, far better than an anticipated drop of more than 1%.
More from Video
CAG has hung onto the bulk of its recent gains, and could rise to the $50 area, according to the charts and indicators.
Breaking down an approach to the long side of this biotech stock.
AMSC CEO discusses that and China challenges.
One of pharma's biggest CEO's talks M&A action on the exchange.